| Literature DB >> 28050924 |
M Kay Garcia1, Lorenzo Cohen1, Michael Spano1, Amy Spelman1, Yousra Hashmi1, Alejandro Chaoul1, Qi Wei1, Gabriel Lopez1.
Abstract
BACKGROUND: Use of complementary and integrative therapies is increasing among cancer patients, but data regarding the impact treatments such as acupuncture have in an inpatient oncology setting are limited.Entities:
Keywords: acupuncture; cancer; inpatient; integrative medicine; oncology
Mesh:
Year: 2017 PMID: 28050924 PMCID: PMC5950949 DOI: 10.1177/1534735416685403
Source DB: PubMed Journal: Integr Cancer Ther ISSN: 1534-7354 Impact factor: 3.279
Figure 1.Patient flow diagram. This diagram depicts patient flow throughout the study.
*IMC – Integrative Medicine Clinic.
Patient Characteristics.
| Characteristic | n (%) |
|---|---|
| Age in years (range, 17-90 years) | |
| <30 | 13 (8) |
| 30-59 | 87 (50) |
| 60-79 | 67 (39) |
| ≥80 | 5 (3) |
| Sex | |
| Female | 100 (58) |
| Male | 72 (42) |
| Race/Ethnicity | |
| Asian | 3 (2) |
| Black | 14 (8) |
| Hispanic | 14 (8) |
| Pacific Islander | 1 (0.5) |
| White | 124 (72) |
| Unknown | 16 (9) |
| Marital status | |
| Married | 125 (73) |
| Single | 27 (16) |
| Divorced | 14 (8) |
| Widowed | 4 (2) |
| Unknown | 2 (1) |
| Type of cancer[ | |
| Breast | 23 (13) |
| Endocrine | 6 (4) |
| Gastrointestinal | 45 (26) |
| Genitourinary | 21 (12) |
| Gynecologic | 15 (9) |
| Head/Neck | 7 (4) |
| Leukemia | 10 (6) |
| Lymphoma/Myeloma | 5 (3) |
| Neurologic | 12 (7) |
| Sarcoma | 3 (2) |
| Skin | 12 (7) |
| Thoracic | 11 (6) |
| Other | 2 (1) |
| SEER stage | |
| Local | 13 (8) |
| Distant | 58 (34) |
| Direct extension–lymph node | 33 (19) |
| Post-treatment, NED | 10 (6) |
| Not available | 58 (34) |
Abbreviations: SEER, Surveillance, Epidemiology, and End Results Staging Program; NED, no evidence of disease at time of study entry.
Twenty percent (n = 35) of patients suffered from multiple types of cancer.
Edmonton Symptom Assessment Change Scores From Baseline to Post-treatment for Patients Who Reported a Symptom Score ≥1.
| Symptom | Baseline | Initial Treatment | Follow-up | |||||
|---|---|---|---|---|---|---|---|---|
| n | Mean (SD) | n | Mean (SD) |
| n | Mean (SD) |
| |
| Pain | 166 | 4.9 (3.0) | 69 | −1.8 (2.2) | <.0001 | 20 | −2.3 (2.7) | .001 |
| Nausea | 164 | 1.6 (2.5) | 30 | −1.2 (1.9) | <.001 | 8 | −2.3 (2.8) | .058 |
| Fatigue | 157 | 5.7 (3.1) | 67 | −0.4 (1.1) | .008 | 19 | −1.2 (3.1) | .12 |
| Sleep disturbance | 152 | 5.0 (3.3) | 61 | −0.3 (1.5) | .12 | 17 | −2.5 (4.4) | .03 |
| Shortness of breath | 160 | 1.9 (2.7) | 25 | −0.04 (1.1) | .85 | 10 | −1.7 (3.4) | .15 |
| Appetite | 152 | 5.1 (3.5) | 58 | −0.3 (1.5) | .16 | 13 | −0.2 (3.7) | .83 |
| Drowsiness | 151 | 4.8 (3.4) | 57 | −0.6 (1.8) | .02 | 16 | −2.0 (2.6) | .008 |
| Depression | 136 | 2.1 (2.8) | 28 | −0.1 (0.9) | .69 | 5 | −2.6 (2.6) | .09 |
| Anxiety | 141 | 2.9 (3.1) | 36 | −0.8 (1.8) | .01 | 9 | −2.4 (1.7) | .002 |
| Well-being | 132 | 4.5 (3.2) | 48 | −0.15 (1.5) | .50 | 12 | −1.2 (2.2) | .10 |
Mean change in score between baseline and initial treatment post-assessment.
Mean change in score between baseline and follow-up post-assessment. P values derived using paired t tests.
Figure 2.Percentage of patients with clinically significant improvement from baseline.
*Clinical significance is defined as ≥1 point reduction on the Edmonton Symptom Assessment Scale (ESAS).[14]